Cobblestone Capital Advisors LLC NY Trims Position in Johnson & Johnson (NYSE:JNJ)

Cobblestone Capital Advisors LLC NY decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,443 shares of the company’s stock after selling 563 shares during the period. Johnson & Johnson comprises 1.3% of Cobblestone Capital Advisors LLC NY’s investment portfolio, making the stock its 20th biggest position. Cobblestone Capital Advisors LLC NY’s holdings in Johnson & Johnson were worth $13,091,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Evolution Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $40,000. Horan Securities Inc. increased its holdings in shares of Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after acquiring an additional 241 shares during the last quarter. Stuart Chaussee & Associates Inc. increased its holdings in shares of Johnson & Johnson by 20.7% in the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 80 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in shares of Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after acquiring an additional 428 shares during the last quarter. Finally, CKW Financial Group increased its holdings in shares of Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after acquiring an additional 128 shares during the last quarter. 66.90% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Marillyn A. Hewson bought 3,000 shares of the stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.23% of the company’s stock.

JNJ has been the topic of a number of recent analyst reports. Goldman Sachs Group initiated coverage on Johnson & Johnson in a report on Tuesday, May 28th. They issued a “buy” rating on the stock. Credit Suisse Group increased their price objective on Johnson & Johnson from $151.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Wells Fargo & Co reiterated an “outperform” rating and issued a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Citigroup increased their price objective on Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Finally, Raymond James increased their price objective on Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $147.30.

Shares of JNJ stock traded up $0.76 during midday trading on Tuesday, hitting $139.78. The company had a trading volume of 6,657,918 shares, compared to its average volume of 6,888,836. Johnson & Johnson has a 52-week low of $120.11 and a 52-week high of $148.99. The company has a market capitalization of $367.86 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 2.39 and a beta of 0.70. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The company had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same period last year, the business posted $2.06 EPS. The company’s revenue was up .1% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Shareholders of record on Tuesday, May 28th will be paid a $0.95 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 annualized dividend and a dividend yield of 2.72%. The ex-dividend date is Friday, May 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.

TRADEMARK VIOLATION NOTICE: “Cobblestone Capital Advisors LLC NY Trims Position in Johnson & Johnson (NYSE:JNJ)” was published by Rockland Register and is the sole property of of Rockland Register. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://rocklandregister.com/2019/06/12/cobblestone-capital-advisors-llc-ny-has-13-09-million-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is a Fibonacci Channel?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.